SCHEMBL3270846

SCHEMBL3270846

COc1cccc(C(=CCSc2ccc(OCC(=O)O)c(I)c2)c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 7/20 0.53
MTNR1A P48039 5/20 0.48
MTNR1B P49286 5/20 0.48
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PKM P14618 1/20 0.43
PPARA Q07869 1/20 0.41
VNN1 O95497 1/20 0.39
FFAR1 O14842 2/20 0.39
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3270677 1.00 PPARD (0.53) PPARDMTNR1AMTNR1BLMNAHTT
SCHEMBL3270089 0.98 PPARD (0.53) PPARDMTNR1AMTNR1BLMNAHTT
SCHEMBL3270413 0.92 PPARD (0.58) PPARDMTNR1AMTNR1BLMNAPPARA
SCHEMBL3270411 0.92 PPARD (0.58) PPARDMTNR1AMTNR1BLMNAPPARA
SCHEMBL3269445 0.91 PPARD (0.52) PPARDMTNR1AMTNR1BLMNAMAPK1
SCHEMBL3275585 0.91 PPARD (0.52) PPARDMTNR1AMTNR1BLMNAMAPK1
SCHEMBL3269357 0.89 PPARD (0.68) PPARDMTNR1AMTNR1BLMNAHTT
SCHEMBL3269359 0.89 PPARD (0.68) PPARDMTNR1AMTNR1BLMNAHTT
SCHEMBL3271616 0.89 PPARD (0.52) PPARDLMNAHTTMAPK1L3MBTL1
SCHEMBL3269111 0.89 PPARD (0.61) PPARDPPARAFFAR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP claimed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US claimed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US claimed
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP disclosed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US disclosed
EP-1558572-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2005-08-03 EP disclosed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US disclosed
WO-2004037776-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070583-A1 Novel compounds, their preparation and use PPARG, PPARD, PPARA PPARD 2/4885MTNR1A 129/4885MTNR1B 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.